Shareholder Alert: Ademi LLP investigates whether Eargo, Inc. has obtained a Fair Price in its transaction with Patient Square Capital

Eargo, Inc. Delist

Eargo, Inc.




MILWAUKEE, Oct. 30, 2023 /PRNewswire/ -- Ademi LLP is investigating Eargo (Nasdaq: EAR) for possible breaches of fiduciary duty and other violations of law in its transaction with Patient Square Capital.

AdemiLogo (PRNewsfoto/Ademi LLP)

Click here to learn how to join the action or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Eargo stockholders are expected to receive only $2.55 per share. The transaction agreement unreasonably limits competing transactions for Eargo by imposing a significant penalty if Eargo accepts a competing bid. Eargo insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Eargo's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Eargo common stock and wish to obtain additional information, please contact Guri Ademi either at or toll-free: 866-264-3995, or                      

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.


Ademi LLP                                                                  

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

Cision View original content to download multimedia:


Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via